IBIO
iBio develops and offers product applications of its iBioLaunch™ and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. Advantages over other systems include: success with proteins difficult or impossible to produce with... other methods; broadly applicable to biologics, including monoclonal antibodies, other therapeutic proteins and vaccines; enables rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more. Additional benefits include a practically unlimited surge capacity for remedial action against bioterrorism and pandemic disease; product entry that is unconstrained by traditional process patents, and significantly lower capital and operating costs for comparable production.
IBIO
Social Links:
Industry:
Biotechnology Genetics Robotics Therapeutics
Founded:
2008-04-01
Address:
Newark, Delaware, United States
Country:
United States
Website Url:
http://www.ibioinc.com
Total Employee:
1+
Status:
Active
Contact:
302-355-0650
Total Funding:
12.27 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Google Universal Analytics Domain Not Resolving Wordpress Plugins
Similar Organizations
Rakuten Medical
Rakuten Medical is a Bio-technology Company.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Emerald Cloud Lab
Emerald Cloud Lab is building technology platforms to drive the future of biotechnology innovation.
Translate Bio
Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.
Current Employees Featured
Founder
Stock Details
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-08-25 | RubrYc Therapeutics | iBio investment in Series A - RubrYc Therapeutics | 7.5 M USD |
Newest Events participated
Official Site Inspections
http://www.ibioinc.com Semrush global rank: 1.9 M Semrush visits lastest month: 11.53 K
- Host name: 151.101.66.159
- IP address: 151.101.66.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "iBio"
iBio – Next Generation Antibody Therapeutics
IBio is pioneering the next generation of antibody therapeutics, leveraging our artificial intelligence-based and epitope steered antibody discovery platformSee details»
Investor Relations :: iBio Inc. (IBIO)
Jan 13, 2025 iBio is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat …See details»
Management Team - iBio Inc.
Mr. Duran served as iBio’s Vice President of Financial Planning and Analysis (FP&A) from April 2021-February 2023. In that capacity, he played a strategic role in the Company’s forecasting, …See details»
People - iBio
At our core, we believe that all value stems from people. Our culture is grounded in diversity, fairness and respect for each individual, creating a space where every team member is heard …See details»
iBio, Inc. (IBIO) Company Profile & Description - Stock Analysis
5 days ago Company profile for iBio, Inc. (IBIO) stock, with a description, list of executives, contact details and other key facts.See details»
iBio and AstralBio Announce Transformative AI drug discovery ...
Mar 27, 2024 For more information, visit www.ibioinc.com. About AstralBio AstralBio is a privately held biotechnology company founded by Patrick Crutcher and several former team …See details»
iBio - Crunchbase Company Profile & Funding
IBio develops and offers product applications of its iBioLaunch™ and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for both …See details»
iBio, Inc. - LinkedIn
IBio, Inc. | 11,033 followers on LinkedIn. AI-Powered Precision Antibody Therapeutics | iBio is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next ...See details»
iBio Announces CEO Departure - GlobeNewswire
Dec 2, 2022 “Tom has helped iBio’s transformation into an AI-powered antibody discovery and development organization,” said Mr. Clark. “Tom’s leadership in the establishment of a …See details»
iBio Company Profile - Office Locations, Competitors, Revenue
Oct 29, 2024 iBio has 5 employees across 2 locations and $225 k in annual revenue in FY 2024. See insights on iBio including office locations, competitors, revenue, financials, executives, …See details»
iBio Strengthens Board with Appointment of Two New …
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the appointment of biotech …See details»
iBio’s Epitope-Steered Antibody Discovery Engine
IBio’s Drug Discovery Platform 2 aims to increase the likelihood of success. Using artificial intelligence (AI), our platform efficiently and consistently delivers antibody candidates against …See details»
iBio - VentureRadar
"iBio is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health with pipeline candidates targeting systemic sceleroderma (IBIO …See details»
iBio Inc Company Profile - Overview - GlobalData
IBio Inc (iBio) is a preclinical-stage biotechnology company that utilizes artificial intelligence (AI) for the development of precision antibodies. Its pipeline products include IBIO-101 for the …See details»
iBio - Overview, News & Similar companies | ZoomInfo.com
View iBio (www.ibioinc.com) location in Texas, United States , revenue, industry and description. Find related and similar companies as well as employees by title and much more.See details»
iBio Announces New Investments from Board Members and Officers
SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the closing of a private …See details»
iBio Strengthens Board with Appointment of Two New …
Nov 25, 2024 “These appointments expand and strengthen our board to align with iBio’s vision of becoming a next-generation antibody discovery and development company with a robust …See details»
iBio Accelerates Transformation to AI-Powered Biotech
Nov 3, 2022 BRYAN, Texas and SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) an AI-driven innovator of precision antibody …See details»
Press Releases - iBio Inc.
Jan 13, 2025 iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBioSee details»